Open Access<p>Targeting cell cycle protein in gastric cancer with CDC20siRNA and anticancer drugs (doxorubicin and quercetin) co-loaded cationic PEGylated nanoniosomes</p>
Author(s) -
Mahdie Hemati,
Fateme Haghiralsadat,
Fariba Jafary,
Seyedmohammad Moosavizadeh,
Ali Moradi
Publication year - 2019
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s211844
Subject(s) - niosome , cationic liposome , pharmacology , gene silencing , oncogene , doxorubicin , cancer cell , cancer , cell cycle , drug delivery , apoptosis , cancer research , drug , chemistry , materials science , medicine , transfection , nanotechnology , biochemistry , chemotherapy , gene , vesicle , membrane
In a past study, we developed and optimized a novel cationic PEGylated niosome containing anticancer drugs (doxorubicin or quercetin) and siRNA. This study intended to evaluate the anti-tumor effects of the combination therapy to target both the proteins and genes responsible for the development of gastric cancer. CDC20, known as an oncogene, is a good potential therapeutic candidate for gastric cancer.